EXAMINING FALSE POSITIVE IGM ANTI-HAV IN MAINE

Trish Bosse, MPH¹, Heidi Mallis, MPH¹,², Susan Manning, MD, MPH¹,³
¹Maine Center for Disease Control and Prevention, Augusta, ME, ²University of Southern Maine, Portland, ME, ³Career Epidemiology Field Officer Program, Centers for Disease Control and Prevention, Atlanta, GA

BACKGROUND

Acute Hepatitis A Virus (HAV) Infection
- Liver disease characterized by malaise, nausea, stomach pain, dark urine, and jaundice
- Fecal-oral transmission (person-to-person, or via contaminated food, water, and raw or undercooked shellfish)
- Incubation period 15-50 days
- Positive Immunoglobulin M (IgM) antibody to hepatitis A virus (anti-HAV) and elevated liver function tests

HAV in Maine
- Reportable condition
- 2006-2011 median number of cases per year was 6.5
- Maine CDC follows up on all suspect acute HAV infections in order to:
  - Rapidly implement preventive measures
  - Identify sources of public health concern
  - Characterize burden of acute HAV infections in the state

PURPOSE AND OBJECTIVES

Recent case investigations revealed a number of false positive IgM anti-HAV tests. This warranted taking a closer look to determine extent of false positive IgM anti-HAV tests in Maine.

Objectives
- Compare hepatitis A cases from 2006-2011 that met the 2011 case definition with those that had positive IgM anti-HAV without clinical or epidemiologic evidence of disease
- Describe characteristics that may explain a false positive IgM anti-HAV result

MATERIALS AND METHODS

Hepatitis A records were extracted from the National Electronic Disease Surveillance System (NEDSS). Statistical analysis software (SAS 9.3) was used to analyze records for cases of positive IgM anti-HAV that occurred in Maine between 2006 and 2011.

CDC/CSTE case definitions for acute hepatitis A were used to determine case classification. The case definition was the same for cases from 2006-2010. A new case definition was adopted in 2011 which is similar to the previous definition with the exception of the clinical case definition. In 2011, a requirement for an aminotransferase level of at least 200 IU/L was added to the clinical case definition.

RESULTS

Between 2006 and 2011—
- 44 cases of acute hepatitis A met the case definition
- 100 cases were reported in persons with a positive IgM anti-HAV without clinical or epidemiologic evidence of disease

The highest proportion of false positives was reported in residents of Cumberland (24%), Androscoggin (17%), and York (10%) counties. Cases of acute HAV infection were generally younger, more often symptomatic, including jaundiced, had higher ALT levels, and were more often a contact of a known case of acute HAV infection (Figure 3).

Figure 3. Selected findings of comparison between cases and non-cases

- Cases (n=44) Non-cases (n=100)
  - Median age 39 years 57 years
  - Symptomatic (%) 100% 14%
  - Jaundiced (%) 55% 6%
  - Elevated ALT (median value) 1293 54
  - Contact with known case of HAV (%) 41% 0%

CONCLUSIONS

The analysis identified the following possible reasons for a false positive IgM anti-HAV result:
- Previous HAV infection with prolonged IgM anti-HAV
- Recent hepatitis A vaccination
- Cross-reaction with other serum factors or medications

RECOMMENDATIONS

- Healthcare providers should limit use of IgM anti-HAV testing to persons with evidence of clinical hepatitis or to those who have had recent exposure to a person with an acute HAV infection
- Providers should not use IgM anti-HAV as a screening tool for asymptomatic persons or as part of testing panels for the workup of non-acute liver function abnormalities